A protocol for transitioning patients with heart failure and a left ventricular assist device to a stepdown unit from the ICU ...
Zacks Investment Research on MSN17h
Bayer's sNDA for Kerendia Label Expansion Gets FDA's Priority ReviewBayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...
Hypertrophic cardiomyopathy, also known as HCM or thick heart syndrome, is a genetic condition that causes your heart muscle ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...
Inter-atrial shunt device therapy has shown mixed results in clinical trials, with clinical 'non-responders' typically showing features of more advanced heart failure. We aimed to analyse the ...
Oncology nurses play essential roles in the emerging field of cardio-oncology, which aims to protect patients’ heart function ...
Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback